Corbion

Corbion lowered its forecast for the adjusted EBITDA margin for 2026 to above 16% (previously around 17%), sending the share price down about 3.8%. Management cited macroeconomic uncertainty and unexpected cost inflation from the Middle East conflict (commodity prices, freight rates, energy costs) as reasons. The revenue growth target (organic 3–6%) and free cash flow (€85–90m) remained unchanged, but weak cash generation in Q2 and a working-capital outflow amplified the market reaction. Analysts viewed the margin revision as negative and the share move as company-specific rather than market-wide. » Más en de.investing.com

Corbion reported Q1 2026 revenue of €294 million and adjusted EBITDA of €37.8 million (margin 12.9%). The stock fell 6.08% to €19.24 after the figures. The Functional Ingredients & Solutions segment is under margin pressure, while Health & Nutrition benefits from robust demand. Free cash flow was seasonally at -€15.7 million; management confirms full-year FCF of €85–90 million and expects near-term improvements from cost reductions. » Más en de.investing.com

Corbion reports undiluted earnings per share of €1.29 for 2025 (+63.3%), driven by a significant expansion in margins; net revenue was €1,267.4m, adjusted EBITDA €204.3m (margin 16.1%, +250 basis points). In Q4, volume and mix growth and organic adjusted EBITDA accelerated, and free cash flow for the year amounted to €90.8m. The board proposes a total distribution of €1.00 per share (€0.64 regular, €0.36 special dividend); net debt fell to 1.5x EBITDA. For 2026 Corbion expects organic revenue growth of 3–6%, an adjusted EBITDA margin of around 17% and free cash flow of €85–90m; in the short term Q1 2026 is likely to be below the strong prior year, and negative currency effects weighed on the market reaction. » Más en de.investing.com